The year 2020 was one of challenges for CASI, as it was for the rest of the world, but the company was able to continue to advance the commercialization of Evomela and jumpstart its clinical development engine. CASI is continuing to execute on its strategy of opportunistically in-licensing assets and the recent trend has been to earlier-stage assets such as its latest acquisition, the Chinese rights to the Phase I broad spectrum anti-cancer drug CB-5339, announced in March.
06 Apr 2021
CASI Pharmaceuticals - Continuing to advance and expand the pipeline
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CASI Pharmaceuticals - Continuing to advance and expand the pipeline
- Published:
06 Apr 2021 - Author:
-
Pages:
5
The year 2020 was one of challenges for CASI, as it was for the rest of the world, but the company was able to continue to advance the commercialization of Evomela and jumpstart its clinical development engine. CASI is continuing to execute on its strategy of opportunistically in-licensing assets and the recent trend has been to earlier-stage assets such as its latest acquisition, the Chinese rights to the Phase I broad spectrum anti-cancer drug CB-5339, announced in March.